Explore
Flagship studies, sector briefs, and recurring reports, by topic.
Long-form data narratives that walk through an argument.
Recurring advisor series, from weekly reads to annual reviews.
The daily policy prescription, generated each morning.
Seven sector deep-dives: banking, trade, energy, agriculture, and more.
Ask the corpus: answers grounded in published work, with citations.
Grounding verified
Chronic infection prevalence, liver-cancer driver
Hepatitis B and C are characterized in the curated note as a problem of chronic infection prevalence and as a driver of liver cancer. That framing matters because it identifies a slow, silent disease burden: most chronic carriers feel well for years while the virus quietly damages the liver, and the cost lands later as cirrhosis and liver cancer that are far more expensive and far less survivable than prevention. The note does not attach a current prevalence value (current_state is null), which is itself a finding: Bangladesh is managing a structural communicable-disease burden without a published, decision-grade surveillance number to steer it. You cannot eliminate what you do not count.
The disease structure favors action. Hepatitis B is preventable by vaccination, transmissible from mother to newborn, and suppressible with treatment. Hepatitis C is now curable with a short oral course. The binding gap is not the existence of tools but the absence of a coordinated programme that finds infections early, vaccinates newborns on time, and links the diagnosed to treatment. The lead body for that programme is the Directorate General of Health Services (DGHS).
Start with surveillance and the birth dose, because they unlock everything else. The surveillance circular converts an unmeasured burden into a steerable number, which is what justifies budget and targets the high-prevalence divisions. The birth dose is the single highest-leverage prevention act and depends only on the existing immunization system, so it can move first. Once a baseline prevalence exists, layer in opt-out screening at primary-care contact points, then connect the diagnosed to a treatment pathway. Blood-supply and injection safety run in parallel from day one since they prevent new infections at near-zero marginal program cost.
The binding constraints are fiscal and operational, not scientific. A cure course and antivirals require a reliable procurement line, and any stockout breaks the trust that makes opt-out screening work. Surveillance demands laboratory capacity that is unevenly distributed, so the baseline will be weakest where the burden may be highest. Birth-dose timeliness depends on deliveries occurring inside the facility system; home deliveries are a structural leak. Politically, a silent disease competes poorly for attention against visible emergencies, so the programme must be anchored in a standing DGHS budget line rather than a one-off campaign.
Hepatitis B and C are a measurable, preventable, and largely treatable driver of liver cancer that Bangladesh is currently managing without a published prevalence number to steer by. DGHS should fix that first with a surveillance baseline and a guaranteed birth dose, then build the screen-and-treat pathway that turns a silent burden into an elimination target.
The figures and responsible bodies cited in this prescription are drawn from the platform's own data and the GovTwin registry listed below.
Drafted by an Opus writer grounded in the facts above. Where the prescription cites a figure, it is drawn from those facts. The diagnosis derives from the BDPolicyLab crisis taxonomy; the responsible body and budget from the GovTwin registry. Recommended actions are the think tank's policy judgment.